143 search results for: symposium
ESPGHAN 2024 | Clinical Management of EoE in Adolescents to Adulthood
Prof. Salvatore Oliva discusses the latest treatment options for adolescents and adults with EoE and the importance of effective transition of care.
ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE
Dr. Dhandapani Ashok discusses patient and caregiver burden in pediatric EoE and the challenges with identifying EoE in a young patient population.
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.
UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.
World Congress on Itch (WCI) 2023 | Miami
Exploration of the shared mechanisms of itch across AD, PN, and CSU as well as the distinct ways itch manifests in each disease.
Translating the Science of CSU: From Pathogenesis to Patient Outcomes
Join Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau as they discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, treatment challenges, and emerging therapies.
Translating the Science of CSU: From Pathogenesis to Patient Outcomes
Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU
Dr. Kim discusses the roles of type 2 cytokines at the neuroimmune axis in PN and CSU and conveys how neuroimmune interactions give rise to chronic itch and skin lesions in each disease
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria
Dr. Elmariah, Professor Metz, and Dr. Kim discuss the unique clinical presentations of PN and CSU and explore the shared and distinct pathophysiological underpinnings of itch and inflammation in both diseases, with a focus on the roles of type 2 cytokines at the neuroimmune axis In PN and CSU.
